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Poster Session I S319relationship between social worker and patient was positively im-
pacted and the medical team gained insight into the psychological
impact of treatment. Qualitative findings have been obtained during
the initial demonstration project: IRB approval pending for follow-
up study in 2011/2012.
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VORICONAZOLE THERAPEUTIC MONITORING IN A LEUKEMIA AND BONE
MARROW TRANSPLANT CENTER
Leech, M.1, LaPorte, J.1, Mihelic, R.1, Sanacore, M.1, Sizemore, C.1,
Zhang, X.2, Penland, P.1, Holland, H.K.2, Morris, L.E.2, Bashey, A.2,
Solomon, S.R.2 1The Blood and Marrow Transplant Program, Northside
Hospital, Atlanta, GA; 2The Blood and Marrow Transplant Group of
Georgia, Atlanta, GA
Objectives: The FDA recommends voriconazole (VOR) levels
$0.5mg/L, however current literature recommends trough concen-
trations of $1-2mg/L and \5.5mg/L. We implemented a VOR
therapeutic monitoring program based on our current algorithm
which strives for a level of $0.5 for prophylaxis and $2 for em-
piric/treatment therapy. Our primary objective was to determine
the likelihood of achieving therapeutic levels, and if dose modifica-
tion can be helpful in optimizing attainment of therapeutic levels.
Methods: We prospectively studied steady state VOR levels in 89
consecutive patients (pts) between 02/2010 and 07/2011. Pts in the
prophylaxis group received 200mg BID. Pts in the empiric group re-
ceived 6mg/kg BID for two doses, followed by 4mg/kg BID. Fifty of
the pts had undergone allogeneic HSCT (56%), 38 were undergoing
leukemia therapy (43%), and 1 was an autologous transplant pt.
GVHD was documented in 20/50 HSCT pts (40%), and 5 of those
had gut GVHD.
Results: VOR was being used as prophylaxis in 49/89 pts (55%). A
target level of $0.5 mg/L was achieved in 86% (42/49) of pts. The
level was $1, $2, and $5.5 mg/L in 61%, 43%, and 0%, respec-
tively. Of the 7 pts not reaching $0.5, five doses were increased
with subsequent level $0.5 mg/L. VOR was being used for empiric
therapy in 40/89 pts (45%). Levels achieved target of$2 mg/L in 30
(75%) of 40 pts. Levels were$0.5,$1, and$5.5mg/L in 85%, 82%,
and 40%, respectively. Of the 10 pts with levels\2 mg/L, VOR was
discontinued in 3 pts and dose was increased in 6 pts. Of the 6 in-
creased doses, 3 follow-up levels were obtained and 2 were $2.
The dose of VOR was decreased in 9 pts with level $5.5. Patients
receiving prophylactic VOR were statistically more likely to achieve
targeted levels ($0.5) than pts receiving empiric VOR ($2) (96% vs
80%, p 5 0.038). The presence of gut GVHD was associated with
a statistically significant decrease in achievement of therapeutic
VOR levels compared with GVHD pts without gut involvement
(60% vs 100%, p 5 0.034). However, all GVHD pts achieved ther-
apeutic levels after dose modification.
Conclusion: Utilizing a prospective VOR monitoring program, we
were able to demonstrate that the majority of unselected leukemia
and HSCT pts achieve therapeutic VOR levels. VOR level monitor-
ing allowed for documentation of compliance, gave opportunity for
dose modification to ensure achievement of therapeutic levels, and
reduced toxicity by identifying super-therapeutic levels.305
MUC1 INHIBITION REVERSES THE POOR IMMUNOGENICITY OF LEUKE-
MIA STEM CELLS RENDERING THEM SUSCEPTIBLE TO IMMUNOTHERAPY
Rosenblatt, J.1, Stroopinsky, D.1, Mills, H.1, Luptakova, K.1, Vasir, B.2,
Joyce, R.M.1, Levine, J.D.1, Tzachanis, D.1, Arnason, J.1, Galinsky, I.2,
Stone, R.2, Kufe, D.2, Reiter, Y.3, Avigan, D.E.1 1Beth Israel Deaconess
Medical Center, Boston, MA; 2Dana-Farber Cancer Institute, Boston,
MA; 3Technion-Israel Institute of Technology, Haifa, Israel
Acute myeloid leukemia (AML) arises from a leukemia stem cell
(LSC) population that is resistant to cytotoxic therapy and serves
as a reservoir for relapse. We have demonstrated that the MUC1 tu-
mor antigen is selectively expressed by LSCs but not normal hema-
topoietic stem cells. We subsequently assessed whether LSCs
effectively present MUC1 antigen providing a therapeutic target
for cellular immunotherapy. To investigate this issue we utilized
a novel class of human T Cell Receptor-Like Antibodies (TCRL)which target MUC1 peptide-HLA-A2.1 complex and can be used
to quantify the density of antigen presentation by LSCs.CD34+ cells
were isolated from HLA-A2.1 AML patients and were analyzed for
expression of MUC1 protein with the DF3 anti-MUC1 antibody
and for HLA presentation of MUC1 peptide with the HLA-A2.1/
MUC1 TCRL. Remarkably, despite the strong surface expression
of the MUC1 protein (mean expression 68%, n 5 8), low levels of
HLA bound MUC1 peptide was detected (mean expression 7.6%,
n 5 8). Similarly, leukemia progenitors minimally express HLA-
A2-WT1 peptide complexes (mean expression 5%, n 5 3). These
findings suggest that leukemia progenitors exhibit an immuno-priv-
ileged phenotype, potentially shielding them from immunotherapy.
We have developed aMUC1 inhibitor peptide, G0-203, that induces
differentiation and apoptosis of leukemia progenitors. We evaluated
whether, in addition to inducing differentiation of leukemia progen-
itors, exposure to GO-203 would augment antigen presentation. Ex-
posure of CD34+ AML cells to 5mM GO-203 for 24 hours
upregulated the mean expression of HLA-A2.1/MUC1 peptide
complexes (10% to 62%; n 5 4, p 5 0.001). Consistent with these
findings, GO-203-treated leukemia progenitors exhibited an in-
crease in potency as antigen presenting cells, as manifested by their
stimulation of autologous T cells and expansion of antigen specific
T cells. In addition, GO-203 exposure increased susceptibility of
leukemia progenitors to targeting by T cells stimulated by an autol-
ogousDC/AML fusion vaccine, as manifested by a 3 -fold increase in
Granzyme B activity. In conclusion, the results demonstrate that
leukemia progenitors exhibit low levels of antigens presentation, re-
sulting in their poor immunogenicity and potential resistance to im-
munotherapy. Exposure of leukemia progenitors to a MUC1
inhibitor peptide, GO-203, upregulates HLA presentation of leuke-
mia associated antigens, rendering these cells more susceptible to
immune targeting.
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USE OF THE VETERANS AFFAIRS NUTRITIONAL STATUS CLASSIFICATION
SCHEME IN THE EVALUATION OF SURVIVAL AFTER AUTOLOGOUS PE-
RIPHERAL BLOOD STEM CELL TRANSPLANTATION
Toro, J.J.1,2, Haile, D.J.1, Lee, S.1, Jewell, P.S.1, Freytes, C.O.1,2 1South
Texas Veterans Health Care System, Audie L. Murphy Memorial Vet-
erans Hospital, San Antonio, TX; 2University of Texas Health Science
Center at San Antonio, San Antonio, TX
Background:We have previously reported that the Veterans Affairs
Nutritional Status Classification Scheme (VA-NSCS) can identify
patients (pts) at a higher risk of acute toxicities after autologous pe-
ripheral blood stem cell transplantation (APBSCT) but no studies
have been performed to analyze the impact of the VA-NSCS on sur-
vival [Toro et al, Biol BloodMarrow Transplant 2009;15:1060]. We
analyzed the correlation between the VA-NSCS and survival rates
after APBSCT.
Methods: A total of 231 consecutive pts who underwent APBSCT
for hematologic malignancies at the Audie L. Murphy Memorial
VeteransHospital, between June 2005 andDecember 2010, were an-
alyzed. A registered dietician assessed the nutritional status (NS) of
the pts utilizing the VA-NSCS prior to the administration of the
conditioning regimen. Pretransplant patient characteristics and
posttransplant data on toxicities were obtained from the transplant
program database.
Results: The median age of the study subjects was 60 years (range
19-78). Of the 231 pts, 221 (96%) were males and 127 (55%) were
Caucasian. One hundred sixty-six (72%) pts had multiple myeloma
and received melphalan as conditioning regimen. Sixty-five (28%)
pts had lymphoma and received either BEAM or CVB as condition-
ing regimen. Eighty-two (35%) of the pts had a normal NS, 137
(59%) had mildly compromised NS and 12 (5%) had moderately
compromised NS. No statistically significant differences between
the 3 nutritional status groups were observed with respect to age,
ethnicity or diagnosis. The overall survival (OS) rate at 1 year was
97%with non-relapsemortality of 1%.TheOS rates among normal,
mildly andmoderately compromisedNSwere 78% (64 pts), 68% (93
pts), and 42% (5 pts) respectively (P 5 0.011). The pts with normal
NS were 5.0 times as likely to live as pts with moderately compro-
mised NS (95% CI 5 1.41 to 17.57; P 5 0.009). Consistent with
our previous report, the pts with moderately compromised NS expe-
rienced a significant longer length of hospital stay (36.26 31.5 days)
